

PROGRAMME

Sunday 3 July

13.00-17.00	Registration		
			Main auditorium
15.00	Welcome		Gunilla T. Westermark Uppsala, Sweden
	Chair persons		
	Robert Kisilevsky/Angela Dispenzieri		
15.15 – 16.00	Opening lecture	O-1	Giampaolo Merlini Pavia, Italy
	Amyloid and Amyloidosis.		
16.00 – 18.15	Basic science		
16.00 – 16.30	Keynote lecture	O-2	Fredrik Ponten Uppsala, Sweden
	Human protein atlas.		
16.30 – 16.45	Identifying germline genetic risk factors for immunoglobulin light chain amyloidosis.	O-3	Miguel Inacio Da Silva Filho Heidelberg, Germany
16.45 – 17.00	The role of novel biomarkers in al amyloidosis.	O-4	Ga Yeon Lee Seoul, Korea
17.00 – 17.15	Immunotherapy against alpha-synuclein proto-fibrils as a therapeutic strategy for Parkinson's disease.	O-5	Joakim Bergström Uppsala, Sweden
17.15 – 17.30	siRNA targeting the κ light chain constant region: A pre-clinical experimental approach to AL and non-fibrillar κ light chain deposition diseases.	O-6	Xun Ma Boston, MA
17.30 – 17.45	Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: what makes the protein amyloidogenic?	O-7	Olga Gursky Boston, MA
17.45 – 18.00	A method for the early diagnosis of the transthyretin amyloidoses using non-native oligomeric transthyretin-specific peptidomimetic probes.	See PA38	Cecilia Monterio La Jolla, CA
18.00 – 18.15	Evaluation of therapeutic oligonucleotides for familial amyloid polyneuropathy in a stem cell-based in vitro model.	O-71	Christoph Niemetz Munster, Germany
19.00	Welcome reception		Botanical garden

Monday 4 July

			Main auditorium
	Chair persons		
	Marcus Fändrich/Jeffrey W. Kelly		
08.00 – 09.45	Basic science		
08.00 – 08.30	Keynote lecture	O-9	Jan Johansson Stockholm, Sweden
	Chaperone in amyloidosis.		
08.30 – 09.00	Keynote lecture	O-10	David Eisenberg

	Amyloid and amyloids.		Los Angeles, CA
09.00 – 09.15	A bifunctional peptide, “peptope”, for pre-targeting antibody 7D8 to systemic amyloid deposits.	O-11	Jonathan Wall Knoxville, TN
09.15 – 09.30	Acceleration of α -synuclein aggregation.	O-12	Ricardo Gaspar Lund, Sweden
09.30 – 09.45	Carbamylation of the amino-terminal residue (Gly 1) of mouse SAA1.1 promotes amyloid fibril formation.	O-13	Barbara Kluge-Beckerman Indianapolis, IN
09.45 – 10.15	Coffee break		
	Chair persons Jan Johansson/Joel N. Buxbaum		
10.15 – 12.00	Basic science		
10.15 – 10.45	Keynote lecture Seeding and cross-seeding.	O-14	Christopher M. Dobson Cambridge, UK
10.45 – 11.00	Co-fibrillogenesis of wild-type and D76N β 2-microglobulin: seeding effect or prion-like mechanism?	O-15	Vittorio Bellotti Pavia, Italy and London, UK
11.00 – 11.15	Molecular determinants of IAPP cross-amyloid interaction with A β .	O-16	Aphrodite Kapurniotu Munich, Germany
11.15 – 11.30	Cross-seeding of medin and A- β amyloid.	O-17	Hannah Davies Liverpool, UK
11.30 – 12.00	Keynote lecture Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P-component.	O-18	Sir Mark B. Pepys London, UK
12.00 – 13.30	Lunch and poster viewing		
	Chair persons Maria Picken/Vaishali Santhorawala		
13.30 – 15.00	Imaging		
13.30 – 14.00	Keynote lecture <i>In vivo</i> detection of amyloid.	O-19	Philip N. Hawkins London, UK
14.00 – 14.15	Regression of cardiac AL amyloidosis demonstrated by cardiovascular magnetic resonance: a new era of understanding.	O-20	Ana Martinez Naharro London, UK
14.15 – 14.30	Visualisation of transthyretin heart amyloidosis by ¹¹ C-PIB and PET.	O-21	Bjorn Pilebro Umeå, Sweden
14.30 – 14.45	Multicenter experience of planar technetium pyrophosphate cardiac imaging: Does preferential cardiac uptake predict survival in patients with ATTR cardiac amyloidosis?	O-22	Adam Castano New York, NY
14.45 – 15.00	Cardiac amyloid imaging with ¹⁸ Fflorbetaben positron emission tomography: a pilot study	O-23	Peter Mollee Queensland, Australia
15.00 – 15.30	Coffee break		
	Chair persons		

	Gunilla Westermark/Ole Suhr		
15.30 – 16.30	Transthyretin		
15.30 – 16.00	Keynote lecture Transthyretin amyloidosis.	O-24	Merrill D. Benson Indianapolis, IN
16.00 – 16.30	Keynote lecture Antibody therapy for transthyretin related familial amyloid polyneuropathy-another therapeutic option.	O-25	Yukio Ando Kumamoto, Japan
16.30 – 18.00	Poster presentations		
19.00 – 21.00	Satellite symposium <i>Alnylam</i>		

Tuesday 5 July

			Main auditorium
08.00 – 10.00	Non-hereditary and hereditary ATTR amyloidosis		
08.00 – 09.30	Pathways for ATTR amyloid formation. Presentations and discussion.	O-26	Vittorio Bellotti Pavia, Italy and London, UK
		O-27	David Eisenberg Los Angeles, CA
		O-28	Jeffrey W. Kelly La Jolla, CA (Chair)
		O-29	Ole B. Suhr Umea, Sweden
		O-30	Per Westermark Uppsala, Sweden
	Chair persons Yukio Ando/Marcia W. Cruz		
9.30 – 09.45	Retinol Binding Protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis.	O-31	Frederick Ruberg Boston, MA
09.45 – 10.00	Establishment of a diagnostic center for amyloidosis in Japan by Kumamoto University.	O-32	Taro Yamashita Kumamoto, Japan
10.00 – 10.30	Coffee break		
10.30 – 10.45	Male gender is a risk factor for myocardial involvement in transthyretin-related amyloidosis: A study based on the Transthyretin Amyloid Outcomes Survey.	O-33	Claudio Rapezzi Bologna, Italy
10.45 – 11.00	Unveiling transthyretin cardiac amyloidosis as an etiology for paradoxical low-flow severe aortic stenosis in patients undergoing transcatheter aortic valve replacement.	O-34	Adam Castano New York, NY
11.00 – 13.00	Satellite symposium <i>Pfizer</i>		Main auditorium

13.00 – 14.00	Lunch		
14.00 –	AL amyloidosis		
	Chair persons Arnoud Jaccard/Ute Hegenbart		
14.00 – 14.30	Keynote lecture AL amyloidosis	O-35	Raymond L. Comenzo Boston, MA
14.30 – 14.45	Limited duration treatment with bortezomib and methylprednisone is effective in primary amyloidosis leading to results similar to those of high dose melphalan.	O-36	Rafat Abonour Indianapolis, IN
14.45 – 15.00	Renal outcome among patients with systemic AL amyloidosis who present with advanced CKD is dependent on speed and magnitude of response to chemotherapy.	O-37	Tamer Rezk London, UK
15.00 – 15.15	CS-1 chimeric antigen receptor adoptive T cell therapy for systemic light chain amyloidosis.	O-38	Xiuli Wang Vuarte, CA
15.15 – 15.30	NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study.	O-39	Morie A. Gertz Rochester, MN
15.30 – 17.30	Coffee Poster presentations		
17.30-	Satellite symposium Prothena		

Wednesday 6 July

	More AL amyloidosis		Main auditorium
08.00 - 09.15	Debate Treatment of AL amyloidosis Stem cell transplantation or chemotherapy for front-line treatment of AL?	O-40 O-41 O-42 O-43	Morie A. Gertz Rochester, MN Glampaolo Merlini Pavia, Italy Stephan Schönland, (Chair), Heidelberg, Germany Martha Skinner, Boston, MA
09.15 - 09.30	A randomized phase iii trial of melphalan and dexamethasone (mdex) versus bortezomib, melphalan and dexamethasone (bmdex) for untreated patients with AL amyloidosis.	See PB-86	Giovanni Palladini Pavia, Italy
09.30 - 10.00	Coffee break		
10.00 - 11.00	AA amyloidosis		

	Chair persons Steven Zeldenrust/Lawreen Connors		
10.00 - 10.30	Keynote lecture Pathogenesis and status of AA amyloidosis	O-44	Bouke P.C. Hazenberg Groningen, the Netherlands
10.30 - 10.45	AA amyloidosis related to mediterranean fever: a cohort study of 31 cases.	O-45	Sophie Georgin-Laville Paris, France
10.45 - 11.00	A clinical phase 3 confirmatory trial of Kiacta™ in the treatment of AA amyloidosis.	O-48	Giampaolo Merlini Pavia, Italy
11.00 - 12.30	Satellite symposium Bellus		Main auditorium
12.30 - 14.00	Lunch and poster presentations		
	Chair persons Arie Stangou/Keiichi Higuchi		
14.15 - 15.05	Other amyloid forms		
14.15 - 14.30	Passive treatment with monoclonal antibodies to islet amyloid polypeptide significantly improved both hemoglobin a1c and glucose tolerance and decreased extracellular amyloid deposits in the transgenic hip rat model of type 2 diabetes	O-49	Wagner Zago San Francisco, CA
14.30 - 14.45	Prevalence of monoclonal gammopathy of unknown significance in ATTR-wildtype patients	O-50	Hallie Geller Boston, MA
14.45 - 15.05	Apolipoprotein C-II amyloidosis Amyloidosis Derived from apolipoprotein C-II: A novel type of renal amyloidosis. Renal amyloidosis associated with a novel ApoC-II variant.	O-51 O-52	Laura Obici, Pavia, Italy Samih Nasr Rochester, MN
15.05 - 15.30	Coffee break		
15.30 - 17.30	Parallel sessions: A. Liver and heart transplantation in amyloidosis B. Animal models		In Main auditorium In Hall B
15.30 –17.30	A. Liver and heart transplantation in amyloidosis		Main auditorium
	Chair persons Bo-Göran Ericzon/Philip Hawkins		
15.30 –16.00	Keynote Lecture Liver transplantation	O-53	Bo-Göran Ericzon Stockholm, Sweden
16.00 –16.30	Keynote lecture Heart transplantation	O-54	Mathew Maurer New York, NY
16.30-16.45	Transthyretin-type cerebral amyloid angiopathy in post-transplant patients with hereditary ATTR amyloidosis: Correlates between clinical findings and PIB-PET imaging	O-55	Yoshiki Sekijima Matsumoto, Japan

16.45 - 17.00	Evaluation of central nervous complications following liver transplantation in patients with hereditary transthyretin amyloidosis.	O-56	Nicklas Wange Umeå, Sweden
17.00 - 17.15	Polyneuropathy after FAP domino liver transplantation.	O-57	Göran Solders Stockholm, Sweden
17.15 - 17.30	Cardiac dysautonomia predicts long term survival in hereditary transthyretin amyloidosis after liver transplantation.	O-58	Michel Slama Paris, France
15.30 – 17.30	B. Animal Models		Hall B
15.30 – 16.45	Presentation and discussion. Experimental models	O-59	Joel N. Buxbaum La Jolla, CA (Chair)
		O-60	Francesca Lavatelli Pavia, Italy
		O-61	Maria J Saraiva Porto, Portugal
		O-62	Gunilla T. Westermark Uppsala, Sweden
	Chair persons Jean D. Sipe/Joel Buxbaum		
16.45 – 17.00	Exploring the mechanism of cardiotoxicity in al amyloidosis: the C. elegans model.	O-63	Paola Rognoni Pavia, Italy
17.00 – 17.15	Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.	O-64	Maria J. Saraiva Porto, Portugal
17.15 – 17.30	Serum amyloid A in the treatment of sepsis in a mouse model	O-65	Reinhold P. Linke Martinsreid, Germany
19.00	Dinner at Uppsala Castle		

Thursday 7 July

08.00 – 10.15	Parallel sessions General discussions		
			Main auditorium
08.00 – 09.15	Discussion I Suitable methodology for treatment evaluation	O-66	Teresa Coelho; Porto, Portugal
		O-67	Thibaud Damy, Paris, France
		O-68	Steven Zeldenrust, Rochester, MN (Chair)
	Chair persons Teresa Coelho/Raymond Comenzo		
09.15 – 09.30	The 6-minute walk test in AL myloidosis patients: a single center experience.	O-69	Vina Pulido Boston, MA
09.30 – 09.45	Characteristics and Outcomes in 179 Patients with Advanced Cardiac (stage	O-70	Ashutosh Wechalekar

	IIIb) AL Amyloidosis from the ALchemy study cohort.		London, UK
9.45 – 10.00	Treatment of transthyretin cardiomyopathy with a TTR specific antisense oligonucleotide (IONIS-TTR Rx)	O-72	Merrill D. Benson Indianapolis, IN
08.00 – 09.15	Discussion II		Hall B
	ThT assay pitfalls- can the method be standardised?	O-73 O-74 O-75 O-76	Jeffrey W. Kelly, La Jolla, CA Hironobu Naiki, Fukui, Japan Sofie Nyström, Linköping, Sweden Daniel Otzen, Aarhus, Denmark (Chair)
	Chair persons Daniel Otzen/Per Westermark		
09.15 – 09.30	FRET-based observation of intracellular SAA fibril formation.	O-77	Stephanie Claus Ulm, Germany
09.30 – 09.45	First report of MYD88 L265P somatic mutation in IgM-associated light chain amyloidosis.	O-78	Rajshekhhar Chakraborty Rochester, MN
09.45 – 10.00	Cell damage in light chain amyloidosis: fibril internalization toxicity and cell-mediated seeding.	O-79	Marta Marin-Argany Rochester, MN
10.00 – 10.15	Discovery of transthyretin stabilizers displaying resilience to the effect of the V30M mutation.	O-80	Rui Brito Porto, Portugal
10.15 – 10.45	Coffee		
			Main auditorium
10.45 – 11.30	ISA members meeting: Report on the journal Amyloid (Per Westermark, editor). Election results. Future symposia.		Bouke P.C. Hazenberg/Angela Dispenzieri
11.30 – 12.00	Summary of the meeting		Martha Skinner Boston, MA
12.00	Closing remarks		Gunilla T. Westermark Ole B. Suhr Per Westermark
12.30 – 13.30	Grab & go lunch		